<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Diabetes Care</journal-id><journal-id journal-id-type="iso-abbrev">Diabetes Care</journal-id><journal-id journal-id-type="hwp">diacare</journal-id><journal-id journal-id-type="pmc">dcare</journal-id><journal-id journal-id-type="publisher-id">Diabetes Care</journal-id><journal-title-group><journal-title>Diabetes Care</journal-title></journal-title-group><issn pub-type="ppub">0149-5992</issn><issn pub-type="epub">1935-5548</issn><publisher><publisher-name>American Diabetes Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19808912</article-id><article-id pub-id-type="pmc">2797957</article-id><article-id pub-id-type="publisher-id">1029</article-id><article-id pub-id-type="doi">10.2337/dc09-1029</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject><subj-group><subject>Emerging Treatments and Technologies</subject></subj-group></subj-group></article-categories><title-group><article-title>Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy</article-title><subtitle>Depression is a major confounding factor</subtitle></title-group><contrib-group><contrib contrib-type="author"><name><surname>Selvarajah</surname><given-names>Dinesh</given-names></name><degrees>MRCP, MBCHB</degrees><xref ref-type="aff" rid="aff1"></xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Gandhi</surname><given-names>Rajiv</given-names></name><degrees>MRCP, MBCHB</degrees><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Emery</surname><given-names>Celia J.</given-names></name><degrees>PHD</degrees><xref ref-type="aff" rid="aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Tesfaye</surname><given-names>Solomon</given-names></name><degrees>FRCP, MD</degrees><xref ref-type="aff" rid="aff1"></xref></contrib><aff id="aff1">From the Diabetes Research Department, Royal Hallamshire Hospital, Sheffield, U.K.</aff></contrib-group><author-notes><corresp id="cor1">Corresponding author: Dinesh Selvarajah, <email>dinesh.selvarajah@gmail.com</email>.</corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2010</year></pub-date><pub-date pub-type="epub"><day>6</day><month>10</month><year>2009</year></pub-date><volume>33</volume><issue>1</issue><fpage>128</fpage><lpage>130</lpage><history><date date-type="received"><day>15</day><month>6</month><year>2009</year></date><date date-type="accepted"><day>30</day><month>9</month><year>2009</year></date></history><permissions><copyright-statement>© 2010 by the American Diabetes Association.</copyright-statement><copyright-year>2010</copyright-year><license license-type="creative-commons"><license-p>Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/3.0/">http://creativecommons.org/licenses/by-nc-nd/3.0/</ext-link> for details.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="zdc00110000128.pdf"></self-uri><abstract><sec><title><offsets xml_i="3502" xml_f="3511" txt_i="11" txt_f="20">OBJECTIVE</offsets></title><p><offsets xml_i="3522" xml_f="3663" txt_i="21" txt_f="162">To assess the efficacy of Sativex, a cannabis-based medicinal extract, as adjuvant treatment in painful diabetic peripheral neuropathy (DPN).</offsets></p></sec><sec><title><offsets xml_i="3685" xml_f="3712" txt_i="164" txt_f="191">RESEARCH DESIGN AND METHODS</offsets></title><p><offsets xml_i="3723" xml_f="3958" txt_i="192" txt_f="427">In this randomized controlled trial, 30 subjects with painful DPN received daily Sativex or placebo. The primary outcome measure was change in mean daily pain scores, and secondary outcome measures included quality-of-life assessments.</offsets></p></sec><sec><title><offsets xml_i="3980" xml_f="3987" txt_i="429" txt_f="436">RESULTS</offsets></title><p><offsets xml_i="3998" xml_f="4297" txt_i="437" txt_f="736">There was significant improvement in pain scores in both groups, but mean change between groups was not significant. There were no significant differences in secondary outcome measures. Patients with depression had significantly greater baseline pain scores that improved regardless of intervention.</offsets></p></sec><sec><title><offsets xml_i="4319" xml_f="4330" txt_i="738" txt_f="749">CONCLUSIONS</offsets></title><p><offsets xml_i="4341" xml_f="4569" txt_i="750" txt_f="978">This first-ever trial assessing the efficacy of cannabis has shown it to be no more efficacious than placebo in painful DPN. Depression was a major confounder and may have important implications for future trials on painful DPN.</offsets></p></sec></abstract></article-meta></front><body><p><offsets xml_i="4622" xml_f="4721" txt_i="987" txt_f="1086">Painful diabetic peripheral neuropathy (DPN) is a common and distressing complication of diabetes (</offsets><xref rid="B1" ref-type="bibr"><offsets xml_i="4752" xml_f="4753" txt_i="1086" txt_f="1087">1</offsets></xref><offsets xml_i="4760" xml_f="5065" txt_i="1087" txt_f="1392">). Unfortunately, drug treatments are often ineffective and complicated by unwanted side effects. Thus, there is need for better treatment. We report the first randomized placebo-controlled trial assessing the efficacy and safety of a cannabis-based medicinal extract (Sativex) in intractable painful DPN.</offsets></p><sec><title><offsets xml_i="5081" xml_f="5108" txt_i="1393" txt_f="1420">RESEARCH DESIGN AND METHODS</offsets></title><p><offsets xml_i="5119" xml_f="5202" txt_i="1421" txt_f="1504">A total of 38 patients with chronic painful DPN (Neuropathy Total Symptom Score 6 [</offsets><xref rid="B2" ref-type="bibr"><offsets xml_i="5233" xml_f="5234" txt_i="1504" txt_f="1505">2</offsets></xref><offsets xml_i="5241" xml_f="5535" txt_i="1505" txt_f="1790">] &gt;4 and &lt;16) for at least 6 months with stable glycemic control (A1C &lt;11%) were assessed. Those with persistent pain, despite an adequate trial of tricyclic antidepressants, were recruited. All patients gave written informed consent. The study had Sheffield Ethics Committee approval.</offsets></p><p><offsets xml_i="5542" xml_f="6031" txt_i="1791" txt_f="2280">A prospective randomized double-blind placebo-controlled trial design was used. Baseline pain scores were obtained prerandomization. Three modalities of pain (superficial, deep, and muscular pain) were assessed daily using a 100-mm visual analog scale (VAS). The dose of study medication was titrated over 2 weeks, followed by a 10-week maintenance phase. At baseline, depression was assessed using the seven-item depression subscale of the Hospital Anxiety and Depression Scale (HADS-D) (</offsets><xref rid="B3" ref-type="bibr"><offsets xml_i="6062" xml_f="6063" txt_i="2280" txt_f="2281">3</offsets></xref><offsets xml_i="6070" xml_f="6148" txt_i="2281" txt_f="2359">). Patients continued preexisting neuropathic pain treatment during the study.</offsets></p><p><offsets xml_i="6155" xml_f="6596" txt_i="2360" txt_f="2801">Improvement in pain, as assessed by the pain diary and Neuropathic Pain Scale (NPS [4]) questionnaire, was used as the primary outcome measure. Study end point was the final week mean pain and NPS score while taking the maximum tolerated dose of study medication. A total pain score (TPS) (average score of all three pain modalities) was also calculated. Secondary outcome measure was quality of life (QOL), assessed by McGill Pain and QOL (</offsets><xref rid="B5" ref-type="bibr"><offsets xml_i="6627" xml_f="6628" txt_i="2801" txt_f="2802">5</offsets></xref><offsets xml_i="6635" xml_f="6659" txt_i="2802" txt_f="2826">), SF-36 Health Survey (</offsets><xref rid="B6" ref-type="bibr"><offsets xml_i="6690" xml_f="6691" txt_i="2826" txt_f="2827">6</offsets></xref><offsets xml_i="6698" xml_f="6714" txt_i="2827" txt_f="2843">), and EuroQOL (</offsets><xref rid="B7" ref-type="bibr"><offsets xml_i="6745" xml_f="6746" txt_i="2843" txt_f="2844">7</offsets></xref><offsets xml_i="6753" xml_f="6841" txt_i="2844" txt_f="2932">) questionnaires. Tolerability and side effects were evaluated using standardized forms.</offsets></p><p><offsets xml_i="6848" xml_f="7058" txt_i="2933" txt_f="3143">Sativex (tetrahydrocannabinol [27 mg/ml] and cannabidiol [25 mg/ml]) and its matching placebo were presented as a pump-action spray. Doses were administered sublingually in divided doses up to four times a day.</offsets></p><sec><title><offsets xml_i="7074" xml_f="7094" txt_i="3144" txt_f="3164">Statistical analysis</offsets></title><p><offsets xml_i="7105" xml_f="7538" txt_i="3165" txt_f="3595">An intent-to-treat analysis was undertaken. Differences in subgroup baseline characteristics were correlated to the outcome and adjustments performed at a coefficient &gt;0.50. The distributions of outcome measures with each of the covariates were analyzed. Multiple linear regression was used for a normal distribution, while skewed distribution was initially transformed. Data on proportions was analyzed using Fisher's exact test.</offsets></p><p><offsets xml_i="7545" xml_f="7980" txt_i="3596" txt_f="4028">In a post hoc analysis, patients were divided into individuals with depression (HADS-D score ≥10) and no depression (HADS-D score &lt;10). Using ANCOVA, we compared mean change in TPS from baseline between these groups. The interaction between depression and treatment was assessed using two-factor ANOVA. Each treatment arm was divided into patients with and without depression, and outcomes were compared using an independent sample </offsets><italic><offsets xml_i="7988" xml_f="7989" txt_i="4028" txt_f="4029">t</offsets></italic><offsets xml_i="7998" xml_f="8004" txt_i="4029" txt_f="4035"> test.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="8051" xml_f="8058" txt_i="4038" txt_f="4045">RESULTS</offsets></title><p><offsets xml_i="8069" xml_f="8209" txt_i="4046" txt_f="4186">Of 30 patients randomized, 6 withdrew because of adverse events. We excluded one placebo-treated patient from the intent-to-treat analysis (</offsets><italic><offsets xml_i="8217" xml_f="8218" txt_i="4186" txt_f="4187">n</offsets></italic><offsets xml_i="8227" xml_f="8266" txt_i="4187" txt_f="4226"> = 29) because of a protocol violation.</offsets></p><sec><title><offsets xml_i="8282" xml_f="8305" txt_i="4227" txt_f="4250">Primary outcome measure</offsets></title><p><offsets xml_i="8316" xml_f="8490" txt_i="4251" txt_f="4425">Covariates used in the analysis were duration of diabetes, baseline scores, age, and sex. There was no significant difference in mean change TPS between Sativex and placebo (</offsets><italic><offsets xml_i="8498" xml_f="8499" txt_i="4425" txt_f="4426">P</offsets></italic><offsets xml_i="8508" xml_f="8628" txt_i="4426" txt_f="4546"> = 0.40; SEM 9.5; 95% CI −11.3 to 27.8) at end point. Similarly, there was no difference in mean change in superficial (</offsets><italic><offsets xml_i="8636" xml_f="8637" txt_i="4546" txt_f="4547">P</offsets></italic><offsets xml_i="8646" xml_f="8683" txt_i="4547" txt_f="4584"> = 0.72; 9.1; −15.3 to 21.93), deep (</offsets><italic><offsets xml_i="8691" xml_f="8692" txt_i="4584" txt_f="4585">P</offsets></italic><offsets xml_i="8701" xml_f="8746" txt_i="4585" txt_f="4630"> = 0.38; 10.5; −12.2 to 30.8), and muscular (</offsets><italic><offsets xml_i="8754" xml_f="8755" txt_i="4630" txt_f="4631">P</offsets></italic><offsets xml_i="8764" xml_f="8863" txt_i="4631" txt_f="4730"> = 0.26; 10.3; −9.15 to 33.0) pain VAS. Differences in NPS did not reach statistical significance (</offsets><italic><offsets xml_i="8871" xml_f="8872" txt_i="4730" txt_f="4731">P</offsets></italic><offsets xml_i="8881" xml_f="8910" txt_i="4731" txt_f="4760"> = 0.62; 7.8; −20.1 to 12.1).</offsets></p><p><offsets xml_i="8917" xml_f="9045" txt_i="4761" txt_f="4889">Eight (53%) Sativex-treated patients responded (defined as ≥30% total pain VAS improvement) versus nine (64%) placebo patients (</offsets><italic><offsets xml_i="9053" xml_f="9054" txt_i="4889" txt_f="4890">P</offsets></italic><offsets xml_i="9063" xml_f="9108" txt_i="4890" txt_f="4935"> = 0.55, odds ratio 0.63, 95% CI 0.14–2.82) (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="9140" xml_f="9147" txt_i="4935" txt_f="4942">Table 1</offsets></xref><offsets xml_i="9154" xml_f="9156" txt_i="4942" txt_f="4944">).</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="9204" xml_f="9211" txt_i="4945" txt_f="4952">Table 1</offsets></label><caption><p><offsets xml_i="9231" xml_f="9286" txt_i="4952" txt_f="5007">Demographics and primary and secondary outcome measures</offsets></p></caption><table frame="hsides" rules="groups"><thead valign="bottom"><tr><th rowspan="2" colspan="1"></th><th align="center" colspan="2" rowspan="1"><offsets xml_i="9440" xml_f="9448" txt_i="5008" txt_f="5016">Baseline</offsets><hr></hr></th><th align="center" colspan="2" rowspan="1"><offsets xml_i="9505" xml_f="9514" txt_i="5016" txt_f="5025">End point</offsets><hr></hr></th><th align="center" rowspan="2" colspan="1"><italic><offsets xml_i="9579" xml_f="9580" txt_i="5025" txt_f="5026">P</offsets></italic></th></tr><tr><th align="center" rowspan="1" colspan="1"><offsets xml_i="9646" xml_f="9653" txt_i="5026" txt_f="5033">Sativex</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="9701" xml_f="9708" txt_i="5033" txt_f="5040">Placebo</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="9756" xml_f="9763" txt_i="5040" txt_f="5047">Sativex</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="9811" xml_f="9818" txt_i="5047" txt_f="5054">Placebo</offsets></th></tr></thead><tbody valign="top"><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="9901" xml_f="9912" txt_i="5054" txt_f="5065">Age (years)</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="9967" xml_f="9977" txt_i="5066" txt_f="5076">58.2 ± 8.8</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="10032" xml_f="10043" txt_i="5077" txt_f="5088">54.4 ± 11.6</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="10164" xml_f="10168" txt_i="5091" txt_f="5095">0.24</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="10223" xml_f="10235" txt_i="5096" txt_f="5108">Sex (female)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="10290" xml_f="10291" txt_i="5109" txt_f="5110">4</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="10346" xml_f="10347" txt_i="5111" txt_f="5112">7</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="10468" xml_f="10472" txt_i="5115" txt_f="5119">0.38</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="10527" xml_f="10536" txt_i="5120" txt_f="5129">BMI (kg/m</offsets><sup><offsets xml_i="10541" xml_f="10542" txt_i="5129" txt_f="5130">2</offsets></sup><offsets xml_i="10548" xml_f="10549" txt_i="5130" txt_f="5131">)</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="10604" xml_f="10614" txt_i="5132" txt_f="5142">31.9 ± 6.3</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="10669" xml_f="10679" txt_i="5143" txt_f="5153">31.6 ± 8.2</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="10800" xml_f="10804" txt_i="5156" txt_f="5160">0.92</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="10859" xml_f="10882" txt_i="5161" txt_f="5184">Cannabis (previous use)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="10937" xml_f="10938" txt_i="5185" txt_f="5186">2</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="10993" xml_f="10994" txt_i="5187" txt_f="5188">0</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="11115" xml_f="11119" txt_i="5191" txt_f="5195">0.60</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="11174" xml_f="11181" txt_i="5196" txt_f="5203">A1C (%)</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="11236" xml_f="11246" txt_i="5204" txt_f="5214">8.64 ± 1.7</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="11301" xml_f="11311" txt_i="5215" txt_f="5225">8.39 ± 1.6</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="11432" xml_f="11436" txt_i="5228" txt_f="5232">0.72</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="11491" xml_f="11516" txt_i="5233" txt_f="5258">Diabetes duration (years)</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="11571" xml_f="11581" txt_i="5259" txt_f="5269">11.2 ± 8.4</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="11636" xml_f="11646" txt_i="5270" txt_f="5280">13.7 ± 6.0</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="11767" xml_f="11771" txt_i="5283" txt_f="5287">0.37</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="11826" xml_f="11851" txt_i="5288" txt_f="5313">Type of diabetes (type 2)</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="11906" xml_f="11908" txt_i="5314" txt_f="5316">13</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="11963" xml_f="11965" txt_i="5317" txt_f="5319">11</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="12086" xml_f="12090" txt_i="5322" txt_f="5326">0.23</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="12145" xml_f="12173" txt_i="5327" txt_f="5355">Study medication amount (ml)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="12294" xml_f="12305" txt_i="5358" txt_f="5369">0.70 ± 0.38</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="12360" xml_f="12371" txt_i="5370" txt_f="5381">0.73 ± 0.38</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="12426" xml_f="12430" txt_i="5382" txt_f="5386">0.84</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="12485" xml_f="12502" txt_i="5387" txt_f="5404">Pain diary scores</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="12722" xml_f="12738" txt_i="5410" txt_f="5426">Superficial pain</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="12793" xml_f="12804" txt_i="5427" txt_f="5438">52.3 ± 33.0</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="12859" xml_f="12870" txt_i="5439" txt_f="5450">45.9 ± 24.6</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="12925" xml_f="12936" txt_i="5451" txt_f="5462">37.9 ± 32.1</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="12991" xml_f="13002" txt_i="5463" txt_f="5474">30.2 ± 30.1</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="13057" xml_f="13061" txt_i="5475" txt_f="5479">0.72</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13116" xml_f="13125" txt_i="5480" txt_f="5489">Deep pain</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="13180" xml_f="13191" txt_i="5490" txt_f="5501">63.1 ± 29.4</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="13246" xml_f="13257" txt_i="5502" txt_f="5513">47.4 ± 21.4</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="13312" xml_f="13323" txt_i="5514" txt_f="5525">44.5 ± 32.7</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="13378" xml_f="13389" txt_i="5526" txt_f="5537">24.9 ± 29.5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="13444" xml_f="13448" txt_i="5538" txt_f="5542">0.38</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13503" xml_f="13516" txt_i="5543" txt_f="5556">Muscular pain</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="13571" xml_f="13582" txt_i="5557" txt_f="5568">52.0 ± 34.2</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="13637" xml_f="13648" txt_i="5569" txt_f="5580">41.4 ± 28.3</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="13703" xml_f="13714" txt_i="5581" txt_f="5592">37.9 ± 32.9</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="13769" xml_f="13780" txt_i="5593" txt_f="5604">20.4 ± 29.9</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="13835" xml_f="13839" txt_i="5605" txt_f="5609">0.26</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="13894" xml_f="13897" txt_i="5610" txt_f="5613">TPS</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="13952" xml_f="13963" txt_i="5614" txt_f="5625">55.8 ± 26.7</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="14018" xml_f="14029" txt_i="5626" txt_f="5637">44.9 ± 21.5</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="14084" xml_f="14095" txt_i="5638" txt_f="5649">40.1 ± 28.5</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="14150" xml_f="14161" txt_i="5650" txt_f="5661">25.2 ± 28.8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="14216" xml_f="14220" txt_i="5662" txt_f="5666">0.40</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14275" xml_f="14297" txt_i="5667" txt_f="5689">Neuropathic pain scale</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14517" xml_f="14532" txt_i="5695" txt_f="5710">    Total score</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="14587" xml_f="14598" txt_i="5711" txt_f="5722">67.1 ± 19.4</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="14653" xml_f="14664" txt_i="5723" txt_f="5734">63.6 ± 14.0</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="14719" xml_f="14730" txt_i="5735" txt_f="5746">51.6 ± 21.9</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="14785" xml_f="14796" txt_i="5747" txt_f="5758">51.9 ± 24.1</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="14851" xml_f="14855" txt_i="5759" txt_f="5763">0.62</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="14910" xml_f="14935" txt_i="5764" txt_f="5789">McGill pain questionnaire</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15155" xml_f="15172" txt_i="5795" txt_f="5812">    Sensory scale</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="15227" xml_f="15237" txt_i="5813" txt_f="5823">19.2 ± 6.9</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="15292" xml_f="15302" txt_i="5824" txt_f="5834">16.3 ± 6.3</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="15357" xml_f="15367" txt_i="5835" txt_f="5845">14.7 ± 7.2</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="15422" xml_f="15432" txt_i="5846" txt_f="5856">12.5 ± 8.7</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="15487" xml_f="15491" txt_i="5857" txt_f="5861">0.65</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15546" xml_f="15565" txt_i="5862" txt_f="5881">    Affective scale</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="15620" xml_f="15629" txt_i="5882" txt_f="5891">4.6 ± 4.3</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="15684" xml_f="15693" txt_i="5892" txt_f="5901">5.0 ± 3.8</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="15748" xml_f="15757" txt_i="5902" txt_f="5911">3.1 ± 2.3</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="15812" xml_f="15821" txt_i="5912" txt_f="5921">3.6 ± 3.8</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="15876" xml_f="15880" txt_i="5922" txt_f="5926">0.81</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="15935" xml_f="15942" txt_i="5927" txt_f="5934">    VAS</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="15997" xml_f="16006" txt_i="5935" txt_f="5944">7.6 ± 1.8</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="16061" xml_f="16070" txt_i="5945" txt_f="5954">6.9 ± 1.7</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="16125" xml_f="16134" txt_i="5955" txt_f="5964">5.1 ± 2.2</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="16189" xml_f="16198" txt_i="5965" txt_f="5974">3.8 ± 2.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="16253" xml_f="16257" txt_i="5975" txt_f="5979">0.24</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="16312" xml_f="16338" txt_i="5980" txt_f="6006">    Present pain intensity</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="16393" xml_f="16402" txt_i="6007" txt_f="6016">2.5 ± 1.1</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="16457" xml_f="16466" txt_i="6017" txt_f="6026">2.0 ± 1.0</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="16521" xml_f="16530" txt_i="6027" txt_f="6036">2.1 ± 1.1</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="16585" xml_f="16594" txt_i="6037" txt_f="6046">1.4 ± 1.7</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="16649" xml_f="16653" txt_i="6047" txt_f="6051">0.57</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="16708" xml_f="16727" txt_i="6052" txt_f="6071">EQ-5D questionnaire</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="16947" xml_f="16970" txt_i="6077" txt_f="6100">    Health status index</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="17025" xml_f="17036" txt_i="6101" txt_f="6112">0.40 ± 0.21</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="17091" xml_f="17102" txt_i="6113" txt_f="6124">0.43 ± 0.21</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="17157" xml_f="17168" txt_i="6125" txt_f="6136">0.54 ± 0.22</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="17223" xml_f="17232" txt_i="6137" txt_f="6146">0.6 ± 0.2</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="17287" xml_f="17291" txt_i="6147" txt_f="6151">0.87</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17346" xml_f="17367" txt_i="6152" txt_f="6173">    Health status VAS</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="17422" xml_f="17433" txt_i="6174" txt_f="6185">46.0 ± 20.4</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="17488" xml_f="17499" txt_i="6186" txt_f="6197">44.6 ± 21.8</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="17554" xml_f="17565" txt_i="6198" txt_f="6209">58.1 ± 20.5</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="17620" xml_f="17631" txt_i="6210" txt_f="6221">56.4 ± 11.7</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="17686" xml_f="17690" txt_i="6222" txt_f="6226">0.92</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17745" xml_f="17764" txt_i="6227" txt_f="6246">SF-36 questionnaire</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17984" xml_f="18008" txt_i="6252" txt_f="6276">    Physical functioning</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="18063" xml_f="18074" txt_i="6277" txt_f="6288">26.9 ± 15.1</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="18129" xml_f="18140" txt_i="6289" txt_f="6300">30.8 ± 22.7</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="18195" xml_f="18206" txt_i="6301" txt_f="6312">30.5 ± 16.6</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="18261" xml_f="18272" txt_i="6313" txt_f="6324">36.5 ± 27.9</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="18327" xml_f="18331" txt_i="6325" txt_f="6329">0.63</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18386" xml_f="18403" txt_i="6330" txt_f="6347">    Role physical</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="18458" xml_f="18468" txt_i="6348" txt_f="6358">8.9 ± 27.1</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="18523" xml_f="18534" txt_i="6359" txt_f="6370">12.5 ± 23.5</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="18589" xml_f="18600" txt_i="6371" txt_f="6382">12.5 ± 32.1</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="18655" xml_f="18666" txt_i="6383" txt_f="6394">39.3 ± 47.7</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="18721" xml_f="18725" txt_i="6395" txt_f="6399">0.12</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18780" xml_f="18795" txt_i="6400" txt_f="6415">    Bodily pain</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="18850" xml_f="18861" txt_i="6416" txt_f="6427">22.4 ± 15.5</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="18916" xml_f="18927" txt_i="6428" txt_f="6439">25.7 ± 11.3</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="18982" xml_f="18993" txt_i="6440" txt_f="6451">35.6 ± 16.6</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="19048" xml_f="19059" txt_i="6452" txt_f="6463">41.2 ± 24.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="19114" xml_f="19118" txt_i="6464" txt_f="6468">0.64</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19173" xml_f="19191" txt_i="6469" txt_f="6487">    General health</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="19246" xml_f="19257" txt_i="6488" txt_f="6499">33.5 ± 18.7</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="19312" xml_f="19323" txt_i="6500" txt_f="6511">28.4 ± 20.8</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="19378" xml_f="19389" txt_i="6512" txt_f="6523">34.1 ± 18.2</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="19444" xml_f="19455" txt_i="6524" txt_f="6535">29.6 ± 19.5</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="19510" xml_f="19514" txt_i="6536" txt_f="6540">0.78</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19569" xml_f="19581" txt_i="6541" txt_f="6553">    Vitality</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="19636" xml_f="19647" txt_i="6554" txt_f="6565">28.3 ± 23.2</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="19702" xml_f="19713" txt_i="6566" txt_f="6577">30.8 ± 19.2</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="19768" xml_f="19779" txt_i="6578" txt_f="6589">33.9 ± 22.4</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="19834" xml_f="19845" txt_i="6590" txt_f="6601">39.6 ± 19.4</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="19900" xml_f="19904" txt_i="6602" txt_f="6606">0.45</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19959" xml_f="19981" txt_i="6607" txt_f="6629">    Social functioning</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="20036" xml_f="20047" txt_i="6630" txt_f="6641">50.8 ± 32.5</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="20102" xml_f="20113" txt_i="6642" txt_f="6653">48.2 ± 24.9</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="20168" xml_f="20179" txt_i="6654" txt_f="6665">55.4 ± 25.3</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="20234" xml_f="20245" txt_i="6666" txt_f="6677">67.0 ± 27.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="20300" xml_f="20304" txt_i="6678" txt_f="6682">0.08</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20359" xml_f="20377" txt_i="6683" txt_f="6701">    Role emotional</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="20432" xml_f="20443" txt_i="6702" txt_f="6713">38.1 ± 41.1</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="20498" xml_f="20509" txt_i="6714" txt_f="6725">33.3 ± 40.8</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="20564" xml_f="20575" txt_i="6726" txt_f="6737">54.8 ± 46.4</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="20630" xml_f="20641" txt_i="6738" txt_f="6749">47.6 ± 48.4</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="20696" xml_f="20700" txt_i="6750" txt_f="6754">0.76</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20755" xml_f="20772" txt_i="6755" txt_f="6772">    Mental health</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="20827" xml_f="20838" txt_i="6773" txt_f="6784">57.9 ± 22.6</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="20893" xml_f="20904" txt_i="6785" txt_f="6796">57.1 ± 19.9</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="20959" xml_f="20970" txt_i="6797" txt_f="6808">64.4 ± 20.3</offsets></td><td align="char" char="±" rowspan="1" colspan="1"><offsets xml_i="21025" xml_f="21036" txt_i="6809" txt_f="6820">59.4 ± 20.6</offsets></td><td align="char" char="." rowspan="1" colspan="1"><offsets xml_i="21091" xml_f="21095" txt_i="6821" txt_f="6825">0.76</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="21145" xml_f="21154" txt_i="6826" txt_f="6835">Data are </offsets><italic><offsets xml_i="21162" xml_f="21163" txt_i="6835" txt_f="6836">n</offsets></italic><offsets xml_i="21172" xml_f="21392" txt_i="6836" txt_f="7056"> or means ± SD unless otherwise indicated. Pain diary scores derived from 100 mm VAS completed daily. TPS derived from average of superficial, deep, and muscular pain scores. EQ-5D, EuroQOL quality-of-life questionnaire.</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="21450" xml_f="21476" txt_i="7058" txt_f="7084">Secondary outcome measures</offsets></title><p><offsets xml_i="21487" xml_f="21556" txt_i="7085" txt_f="7154">The McGill pain questionnaire showed no difference in sensory scale (</offsets><italic><offsets xml_i="21564" xml_f="21565" txt_i="7154" txt_f="7155">P</offsets></italic><offsets xml_i="21574" xml_f="21632" txt_i="7155" txt_f="7213"> = 0.65; SEM 3.3; 95% CI −5.39 to 8.44), affective scale (</offsets><italic><offsets xml_i="21640" xml_f="21641" txt_i="7213" txt_f="7214">P</offsets></italic><offsets xml_i="21650" xml_f="21683" txt_i="7214" txt_f="7247"> = 0.81; 1.3; −3.0 to 2.4), VAS (</offsets><italic><offsets xml_i="21691" xml_f="21692" txt_i="7247" txt_f="7248">P</offsets></italic><offsets xml_i="21701" xml_f="21758" txt_i="7248" txt_f="7305"> = 0.24; 1.0; −0.91 to 3.4), and present pain intensity (</offsets><italic><offsets xml_i="21766" xml_f="21767" txt_i="7305" txt_f="7306">P</offsets></italic><offsets xml_i="21776" xml_f="21963" txt_i="7306" txt_f="7493"> = 0.57; 0.53; −0.79 to 1.4) between study cohorts. EuroQOL and SF-36 questionnaires showed improvement in both groups, but differences between groups were not statistically significant (</offsets><xref ref-type="table" rid="T1"><offsets xml_i="21995" xml_f="22002" txt_i="7493" txt_f="7500">Table 1</offsets></xref><offsets xml_i="22009" xml_f="22011" txt_i="7500" txt_f="7502">).</offsets></p></sec><sec><title><offsets xml_i="22033" xml_f="22050" txt_i="7504" txt_f="7521">Post hoc analysis</offsets></title><p><offsets xml_i="22061" xml_f="22177" txt_i="7522" txt_f="7638">We excluded one patient (Sativex) because baseline HADS-D was incomplete. Mean HADS-D for patients with depression (</offsets><italic><offsets xml_i="22185" xml_f="22186" txt_i="7638" txt_f="7639">n</offsets></italic><offsets xml_i="22195" xml_f="22221" txt_i="7639" txt_f="7665"> = 10) and no depression (</offsets><italic><offsets xml_i="22229" xml_f="22230" txt_i="7665" txt_f="7666">n</offsets></italic><offsets xml_i="22239" xml_f="22398" txt_i="7666" txt_f="7825"> = 18) were 13.4 ± 3.5 (means ± SD) and 5.94 ± 2.2, respectively. Patients with depression had significantly higher baseline TPS (62.3 ± 22.1 vs. 43.4 ± 24.3; </offsets><italic><offsets xml_i="22406" xml_f="22407" txt_i="7825" txt_f="7826">P</offsets></italic><offsets xml_i="22416" xml_f="22485" txt_i="7826" txt_f="7895"> = 0.05) and greater TPS improvement (−31.6 ± 24.2 vs. −10.7 ± 25.0; </offsets><italic><offsets xml_i="22493" xml_f="22494" txt_i="7895" txt_f="7896">P</offsets></italic><offsets xml_i="22503" xml_f="22723" txt_i="7896" txt_f="8116"> = 0.04, SEM 9.8, 95% CI 0.54–41.1) compared with those without depression. There was no significant interaction between treatment group and depression. However, there was a significant main effect of depression on TPS (</offsets><italic><offsets xml_i="22731" xml_f="22732" txt_i="8116" txt_f="8117">P</offsets></italic><offsets xml_i="22741" xml_f="22934" txt_i="8117" txt_f="8310"> = 0.05), suggesting that in both treatment arms, patients who were depressed were more likely to respond to intervention: Sativex arm, depressed (−36.7 ± 28.6) vs. nondepressed (−4.9 ± 14.4), </offsets><italic><offsets xml_i="22942" xml_f="22943" txt_i="8310" txt_f="8311">P</offsets></italic><offsets xml_i="22952" xml_f="23020" txt_i="8311" txt_f="8379"> = 0.02, −56.5 to −7.2; placebo arm, −26.5 ± 20.7 vs. −17.3 ± 33.1, </offsets><italic><offsets xml_i="23028" xml_f="23029" txt_i="8379" txt_f="8380">P</offsets></italic><offsets xml_i="23038" xml_f="23061" txt_i="8380" txt_f="8403"> = 0.60, −45.9 to 27.6.</offsets></p></sec></sec><sec sec-type="conclusions"><title><offsets xml_i="23112" xml_f="23123" txt_i="8406" txt_f="8417">CONCLUSIONS</offsets></title><p><offsets xml_i="23134" xml_f="23240" txt_i="8418" txt_f="8524">Despite being common, there are few effective treatments that provide symptomatic relief for painful DPN (</offsets><xref rid="B8" ref-type="bibr"><offsets xml_i="23271" xml_f="23272" txt_i="8524" txt_f="8525">8</offsets></xref><offsets xml_i="23279" xml_f="23419" txt_i="8525" txt_f="8665">). For centuries, cannabinoids have been consumed for their analgesic properties and more recently studied in other neuropathic conditions (</offsets><xref rid="B9" ref-type="bibr"><offsets xml_i="23450" xml_f="23451" txt_i="8665" txt_f="8666">9</offsets></xref><offsets xml_i="23458" xml_f="23829" txt_i="8666" txt_f="9037">). In this study, when compared with placebo, Sativex failed to show statistically significant improvements in primary and secondary outcome measures. Depression was identified as a major confounder of study outcome. Patients with depression had higher baseline pain scores and were also more likely to respond favorably to intervention, regardless if Sativex or placebo.</offsets></p><p><offsets xml_i="23836" xml_f="23944" txt_i="9038" txt_f="9146">Most painful DPN trials to date either have not screened for depression or exclude individuals who have it (</offsets><xref rid="B10" ref-type="bibr"><offsets xml_i="23976" xml_f="23978" txt_i="9146" txt_f="9148">10</offsets></xref><offsets xml_i="23985" xml_f="23986" txt_i="9148" txt_f="9149">,</offsets><xref rid="B11" ref-type="bibr"><offsets xml_i="24018" xml_f="24020" txt_i="9149" txt_f="9151">11</offsets></xref><offsets xml_i="24027" xml_f="24210" txt_i="9151" txt_f="9334">). This study demonstrates that depression is potentially a major confounder in chronic pain trials. Future trials should consider screening for depression before recruiting patients.</offsets></p><p><offsets xml_i="24217" xml_f="24356" txt_i="9335" txt_f="9474">As in a number of recent studies, there was a large placebo effect that may have led to a failure to show differences in outcome measures (</offsets><xref rid="B12" ref-type="bibr"><offsets xml_i="24388" xml_f="24390" txt_i="9474" txt_f="9476">12</offsets></xref><offsets xml_i="24397" xml_f="24582" txt_i="9476" txt_f="9661">). This may provide an insight into the nature of pain in DPN and the placebo effect. There is a need for more robust and objective end points for use in clinical trials of painful DPN.</offsets></p><p><offsets xml_i="24589" xml_f="24952" txt_i="9662" txt_f="10025">Use of concomitant medications may be a confounding factor. They were continued because Sativex was proposed for adjunctive use in painful DPN. Also, it was felt ethically inappropriate to discontinue treatments from which patients may be benefiting. This may have attenuated the analgesic response to Sativex. The use of specific painful DPN QOL questionnaires (</offsets><xref rid="B13" ref-type="bibr"><offsets xml_i="24984" xml_f="24986" txt_i="10025" txt_f="10027">13</offsets></xref><offsets xml_i="24993" xml_f="25074" txt_i="10027" txt_f="10108">) may have captured subtle changes missed by the generic ones used in this study.</offsets></p><p><offsets xml_i="25081" xml_f="25385" txt_i="10109" txt_f="10413">Finally, while the search for therapeutic agents to halt or reverse the neuropathic process continues, more effective treatments are required that provide better symptom control with fewer side effects. The assessment of depression may be important when designing future clinical trials into painful DPN.</offsets></p></sec></body><back><fn-group><fn fn-type="financial-disclosure"><p>The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.</p></fn></fn-group><ack><title>Acknowledgments</title><p>This research was supported by a Diabetes U.K. grant.</p><p>No potential conflicts of interest relevant to this article were reported.</p><p>Helen Bowler and Dr. Daniel Witte are acknowledged for their invaluable contribution providing pharmaceutical and statistical advice, respectively.</p></ack><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Davies</surname><given-names>M</given-names></name><name><surname>Brophy</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>R</given-names></name><name><surname>Taylor</surname><given-names>A</given-names></name></person-group>: 
<article-title>The prevalence, severity and impact of painful diabetic peripheral neuropathy in type 2 diabetes</article-title>. 
<source>Diabetes Care</source>
<year>2006</year>;
<volume>29</volume>:
<fpage>518</fpage>–
<lpage>522</lpage></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bastyr</surname><given-names>EJ</given-names><suffix>3rd</suffix></name><name><surname>Price</surname><given-names>KL</given-names></name><name><surname>Bril</surname><given-names>V</given-names></name></person-group>: 
<collab>MBBQ Study Group.</collab>
<article-title>Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy</article-title>. 
<source>Clin Ther</source>
<year>2005</year>;
<volume>27</volume>:
<fpage>1278</fpage>–
<lpage>1294</lpage><pub-id pub-id-type="pmid">16199253</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zigmond</surname><given-names>A</given-names></name><name><surname>Snaith</surname><given-names>R</given-names></name></person-group>: 
<article-title>The hospital anxiety depression scale</article-title>. 
<source>Acto Psychiatr Scand</source>
<year>1983</year>;
<volume>67</volume>:
<fpage>361</fpage>–
<lpage>370</lpage></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galer</surname><given-names>BS</given-names></name><name><surname>Jensen</surname><given-names>MP</given-names></name></person-group>: 
<article-title>Development and preliminary validation of a pain measure specific to neuropathic pain: the Neuropathic Pain Scale</article-title>. 
<source>Neurology</source>
<year>1997</year>;
<volume>48</volume>:
<fpage>332</fpage>–
<lpage>338</lpage><pub-id pub-id-type="pmid">9040716</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Melzack</surname><given-names>R</given-names></name></person-group>: 
<article-title>The McGill Pain Questionnaire: major properties and scoring methods</article-title>. 
<source>Pain</source>
<year>1975</year>;
<volume>1</volume>:
<fpage>277</fpage>–
<lpage>299</lpage><pub-id pub-id-type="pmid">1235985</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jenkinson</surname><given-names>C</given-names></name><name><surname>Coulter</surname><given-names>A</given-names></name><name><surname>Wright</surname><given-names>L</given-names></name></person-group>: 
<article-title>Short form 36 (SF36) health survey questionnaire: normative data for adults of working age</article-title>. 
<source>BMJ</source>
<year>1993</year>;
<volume>306</volume>:
<fpage>1437</fpage>–
<lpage>1440</lpage><pub-id pub-id-type="pmid">8518639</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal">
<collab>The EuroQol Group.</collab>
<article-title>EuroQol: A new facility for the measurement of health-related quality of life</article-title>. 
<source>Health Policy</source>
<year>1990</year>;
<volume>16</volume>:
<fpage>199</fpage>–
<lpage>208</lpage><pub-id pub-id-type="pmid">10109801</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jensen</surname><given-names>TS</given-names></name><name><surname>Backonja</surname><given-names>MM</given-names></name><name><surname>Hernández Jiménez</surname><given-names>S</given-names></name><name><surname>Tesfaye</surname><given-names>S</given-names></name><name><surname>Valensi</surname><given-names>P</given-names></name><name><surname>Ziegler</surname><given-names>D</given-names></name></person-group><article-title>New perspectives on the management of diabetic peripheral neuropathic pain</article-title>. 
<source>Diab Vasc Dis Res</source>
<year>2006</year>;
<volume>3</volume>:
<fpage>108</fpage>–
<lpage>119</lpage><pub-id pub-id-type="pmid">17058631</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kalant</surname><given-names>H</given-names></name></person-group>: 
<article-title>Medicinal use of cannabis: history and current status</article-title>. 
<source>Pain Res Manag</source>
<year>2001</year>;
<volume>6</volume>:
<fpage>80</fpage>–
<lpage>91</lpage><pub-id pub-id-type="pmid">11854770</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Max</surname><given-names>MB</given-names></name><name><surname>Lynch</surname><given-names>SA</given-names></name><name><surname>Muir</surname><given-names>J</given-names></name><name><surname>Shoaf</surname><given-names>SE</given-names></name><name><surname>Smoller</surname><given-names>B</given-names></name><name><surname>Dubner</surname><given-names>R</given-names></name></person-group>: 
<article-title>Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy</article-title>. 
<source>N Engl J Med</source>
<year>1992</year>;
<volume>326</volume>:
<fpage>1250</fpage>–
<lpage>1256</lpage><pub-id pub-id-type="pmid">1560801</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wernicke</surname><given-names>JF</given-names></name><name><surname>Pritchett</surname><given-names>YL</given-names></name><name><surname>D'Souza</surname><given-names>DN</given-names></name><name><surname>Waninger</surname><given-names>A</given-names></name><name><surname>Tran</surname><given-names>P</given-names></name><name><surname>Iyengar</surname><given-names>S</given-names></name><name><surname>Raskin</surname><given-names>J</given-names></name></person-group>: 
<article-title>A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain</article-title>. 
<source>Neurology</source>
<year>2006</year>;
<volume>67</volume>:
<fpage>1411</fpage>–
<lpage>1420</lpage><pub-id pub-id-type="pmid">17060567</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tesfaye</surname><given-names>S</given-names></name><name><surname>Tandan</surname><given-names>R</given-names></name><name><surname>Bastyr</surname><given-names>EJ</given-names><suffix>3rd</suffix></name><name><surname>Kles</surname><given-names>KA</given-names></name><name><surname>Skljarevski</surname><given-names>V</given-names></name><name><surname>Price</surname><given-names>KL</given-names></name></person-group>: 
<collab>the Ruboxistaurin Study Group.</collab>
<article-title>Factors that impact symptomatic diabetic peripheral neuropathy in placebo-administered patients from two 1-year clinical trials</article-title>. 
<source>Diabetes Care</source>
<year>2007</year>;
<volume>30</volume>:
<fpage>2626</fpage>–
<lpage>2632</lpage><pub-id pub-id-type="pmid">17623822</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zelman</surname><given-names>D</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Dukes</surname><given-names>E</given-names></name><name><surname>Tai</surname><given-names>K</given-names></name><name><surname>Brandenburget</surname><given-names>N</given-names></name></person-group>: 
<article-title>Validation of a modified version of the brief pain inventory for painful diabetic neuropathy</article-title>. 
<source>J Pain Symptom Manage</source>
<year>2005</year>;
<volume>9</volume>:
<fpage>401</fpage>–
<lpage>410</lpage><pub-id pub-id-type="pmid">15857744</pub-id></mixed-citation></ref></ref-list></back></article>